Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.57 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.56 |
| ▸ | F12 | P00748 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26935091 | 0.92 | PCSK9 (0.63) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL26935070 | 0.88 | HDAC3 (0.58) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL26935065 | 0.87 | HDAC3 (0.60) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL26935098 | 0.86 | PCSK9 (0.55) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL31046792 | 0.83 | HDAC3 (0.59) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30866243 | 0.82 | HDAC3 (0.58) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25941528 | 0.82 | PCSK9 (0.62) | PCSK9KLKB1 | |
| SCHEMBL31609179 | 0.81 | HDAC3 (0.61) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30866247 | 0.80 | HDAC3 (0.62) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL31615094 | 0.80 | HDAC3 (0.62) | HDAC8HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399362-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | B.A.I. LABORATORIES, LLC | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399362-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | CXCL10, IL23R, CCL11 | HDAC8 2034/4885HDAC3 3181/4885HDAC4 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.